Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 97

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1B
Chunk 97
---
 assets and liabilities: 

    Prepaid expenses 
     517  
     (519)
  
    Accounts payable and accrued expenses 
     869  
     1,233 
  
    Accrued expenses - related parties 
     (343) 
     467 
  
    Net cash used in operating activities 
     (4,180) 
     (9,429)

    CASH FLOWS FROM FINANCING ACTIVITIES 

    Payment to Backstop Parties for Backstop Agreement 
     -  
     (51,606)
  
    Payment to Backstop Parties for Share Consideration 
     -  
     (12,676)
  
    Issuance of common stock pursuant to the Backstop Agreement and Subscription Agreement 
     -  
     14,260 
  
    Proceeds from Backstop Agreement 
     -  
     1,444 
  
    Proceeds from reverse recapitalization 
     -  
     52,070 
  
    Proceeds from 2023 Convertible Note 
     -  
     650 
  
    Proceeds from 2024 Convertible Notes 
     3,400  
     - 
  
    Proceeds from short-term loans, net of issuance costs 
     -  
     8,258 
  
    Proceeds from Common Stock Purchase Agreement 
     -  
     64 
  
    Repayments of short-term loans 
     -  
     (2,100)
  
    Expenses paid by related-party shareholder 
     -  
     35 
  
    Net cash provided by financing activities 
     3,400  
     10,399 
  
    Total change in cash and restricted cash 
     (780) 
     970 
  
    Cash and restricted cash at beginning of period 
     1,004  
     34 
  
    Cash and restricted cash at end of period 
    $224  
    $1,004 

    Supplemental disclosure of non-cash financing activities: 

    Offering costs not yet paid 
    $-  
    $2,049 
  
    Non-cash stock issuances 
    $1,882  
    $16,413 
  
    Non-cash investment in Virion 
    $-  
    $(1,272)
  
    SPA warrant liability upon issuance